News | Prostate Cancer | August 20, 2015

CEO discusses wearable diagnostic coil on Omaha’s CBS Action News 3

Scanmed, prostate/pelvic MRI coil, Omaha, CBS Action News 3, masses

August 20, 2015 — ScanMed LLC CEO Randall Jones, Ph.D., MBA, introduced the prostate/pelvic magnetic resonance imaging (MRI) coil dedicated to prostate cancer detection on Omaha's CBS Action News 3 segment "The Morning Blend."

The landscape of prostate cancer awareness, detection and diagnosis is rapidly changing. ScanMed introduces solution-based MRI coils to the market as well as provides MRI coil repair, refurbishment, engineering, manufacturing, and online coil commerce services.

Jones saw the opportunity to improve prostate cancer detection in 2011, and dedicated his research and design team to the creation of the Prostate/Pelvic Coil. His main goal was to make affordable, non-invasive diagnostic options available to the masses, as he explained to "The Morning Blend" team Mike DiGiacomo and Mary Nelson.

Jones informed the interviewers that the only technology available has been general torso coils, which don't have enough sensitivity to detect cancers, and the endorectal probe, an invasive coil that has given male patients considerable pause (or denial) when it comes to their diagnostic options. Jones believes that this wearable MRI coil will rapidly change this paradigm.

Jones recommends that patients 40+ years old get their prostate specific antigen (PSA) test, as it can be a valid early-warning indicator. If the PSA indicates anything out of the ordinary, he then recommends looking at procedures like MRI instead of turning immediately to a "blind" biopsy, which produces approximately 50 percent false negative results and can cause damage to the prostate organ.

The key to success is the early detection that the Prostate/Pelvic Coil can provide in conjunction with advanced MRI techniques. Jones points out that in terms of later detection, typically the only treatment option presented is total removal of the organ. This typically results in incontinence, impotence or both.

For more information: www.scanmed.com


Related Content

News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Clinical Trials

June 27, 2024 — Prenuvo, which makes whole-body MRI screening for early cancer detection and other diseases, has ...

Time June 27, 2024
arrow
News | Pediatric Imaging

June 25, 2024 — Rady Children’s Hospital-San Diego, one of the nation’s top pediatric health care systems, today ...

Time June 25, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
Subscribe Now